Product Name :
Lorediplon
Description:
Lorediplon is a nonbenzodiazepine of the pyrazolopyrimidine family that is being pursued as a treatment for insomnia but has not completed development. Lorediplon demonstrated a dose-dependent improvement in sleep, whereas zolpidem showed a more sustained WASO effect. No next-day hangover effects were observed. These sleep effects are also consistent with the pharmacokinetic profile of lorediplon. These results warrant clinical trials in patients with insomnia.
CAS:
917393-39-6
Molecular Weight:
394.42
Formula:
C20H15FN4O2S
Chemical Name:
N-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide
Smiles :
CN(C1=CC(=CC=C1F)C1=CC=NC2=C(C=NN12)C(=O)C1=CC=CS1)C(C)=O
InChiKey:
NQPOCLFSADOXBR-UHFFFAOYSA-N
InChi :
InChI=1S/C20H15FN4O2S/c1-12(26)24(2)17-10-13(5-6-15(17)21)16-7-8-22-20-14(11-23-25(16)20)19(27)18-4-3-9-28-18/h3-11H,1-2H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Lorediplon is a nonbenzodiazepine of the pyrazolopyrimidine family that is being pursued as a treatment for insomnia but has not completed development. Lorediplon demonstrated a dose-dependent improvement in sleep, whereas zolpidem showed a more sustained WASO effect. No next-day hangover effects were observed. These sleep effects are also consistent with the pharmacokinetic profile of lorediplon. These results warrant clinical trials in patients with insomnia.|Product information|CAS Number: 917393-39-6|Molecular Weight: 394.42|Formula: C20H15FN4O2S|Synonym:|UNII-VKU6Z23NSY|VKU6Z23NSY|Lorediplon [INN]|SCHEMBL1316601|CHEMBL4303403|DTXSID00238684|BCP24663|EX-A4221|ZINC43207623|AKOS030526996|CS-5271|SB16784|Lorediplon|N-(2-Fluoro-5-(3-(thiophene-2-carbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-methylacetamide|N-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide|Acetamide, N-(2-fluoro-5-(3-(2-thienylcarbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-methyl-|AK548104|AS-56211|HY-19371|GF-015535-00|Q6680290|N-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide|Chemical Name: N-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide|Smiles: CN(C1=CC(=CC=C1F)C1=CC=NC2=C(C=NN12)C(=O)C1=CC=CS1)C(C)=O|InChiKey: NQPOCLFSADOXBR-UHFFFAOYSA-N|InChi: InChI=1S/C20H15FN4O2S/c1-12(26)24(2)17-10-13(5-6-15(17)21)16-7-8-22-20-14(11-23-25(16)20)19(27)18-4-3-9-28-18/h3-11H,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{UDP-Galactose} web|{UDP-Galactose} Anti-infection|{UDP-Galactose} Protocol|{UDP-Galactose} Purity|{UDP-Galactose} manufacturer|{UDP-Galactose} Cancer} |Shelf Life: ≥12 months if stored properly.{{AZD4573} medchemexpress|{AZD4573} Cell Cycle/DNA Damage|{AZD4573} Activator|{AZD4573} Protocol|{AZD4573} References|{AZD4573} manufacturer} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23543429 |Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. doi: 10.1517/13543784.2015.987340. Epub 2014 Nov 25. Review. PubMed PMID: 25423562.Horoszok L, Baleeiro T, D’Aniello F, Gropper S, Santos B, Guglietta A, Roth T. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum Psychopharmacol. 2014 May;29(3):266-73. doi: 10.1002/hup.2395. PubMed PMID: 24911577.Products are for research use only. Not for human use.|
